CureMS
@curems-project.bsky.social
curems.net is a non-profit website dedicated to #AHSCT (i.e., transplant) for #MultipleSclerosis. Visit curems.net to learn more.
New JNNP study: In aggressive #RRMS, AHSCT greatly reduced PIRA: 10% over 10 years vs 49% in patients moving from natalizumab to other DMTs. Findings suggest #AHSCT may target the silent, smoldering processes that drive MS progression.
🟢More on AHSCT and MS at curems.net
🟢More on AHSCT and MS at curems.net
November 25, 2025 at 7:08 AM
New JNNP study: In aggressive #RRMS, AHSCT greatly reduced PIRA: 10% over 10 years vs 49% in patients moving from natalizumab to other DMTs. Findings suggest #AHSCT may target the silent, smoldering processes that drive MS progression.
🟢More on AHSCT and MS at curems.net
🟢More on AHSCT and MS at curems.net
🎉 curems.net turns one!
In 12 months:
🟢 40% Italian, 60% international readers
🟢 1,250+ contacts from 56 countries
🟢 152 scientific papers cited
🟢 Biweekly updates
CureMS.net is becoming a key resource on #AHSCT for patients and professionals. Thanks to all who support and to all the readers! #MS
In 12 months:
🟢 40% Italian, 60% international readers
🟢 1,250+ contacts from 56 countries
🟢 152 scientific papers cited
🟢 Biweekly updates
CureMS.net is becoming a key resource on #AHSCT for patients and professionals. Thanks to all who support and to all the readers! #MS
October 23, 2025 at 7:42 AM
🎉 curems.net turns one!
In 12 months:
🟢 40% Italian, 60% international readers
🟢 1,250+ contacts from 56 countries
🟢 152 scientific papers cited
🟢 Biweekly updates
CureMS.net is becoming a key resource on #AHSCT for patients and professionals. Thanks to all who support and to all the readers! #MS
In 12 months:
🟢 40% Italian, 60% international readers
🟢 1,250+ contacts from 56 countries
🟢 152 scientific papers cited
🟢 Biweekly updates
CureMS.net is becoming a key resource on #AHSCT for patients and professionals. Thanks to all who support and to all the readers! #MS
Kalincik et al. ( #ECTRIMS 2025) compared #AHSCT (152 pts) vs anti-CD20 (Ocrelizumab 752, Rituximab 107).
#AHSCT showed better ARR and EDSS improvement, with no difference in worsening. No DMT outperforms AHSCT in #RRMS.
🟢 Highlights curems.net/benefits-of-...
Poster core.melbourne/wp-content/u...
#AHSCT showed better ARR and EDSS improvement, with no difference in worsening. No DMT outperforms AHSCT in #RRMS.
🟢 Highlights curems.net/benefits-of-...
Poster core.melbourne/wp-content/u...
October 7, 2025 at 4:42 PM
Kalincik et al. ( #ECTRIMS 2025) compared #AHSCT (152 pts) vs anti-CD20 (Ocrelizumab 752, Rituximab 107).
#AHSCT showed better ARR and EDSS improvement, with no difference in worsening. No DMT outperforms AHSCT in #RRMS.
🟢 Highlights curems.net/benefits-of-...
Poster core.melbourne/wp-content/u...
#AHSCT showed better ARR and EDSS improvement, with no difference in worsening. No DMT outperforms AHSCT in #RRMS.
🟢 Highlights curems.net/benefits-of-...
Poster core.melbourne/wp-content/u...
Boffa & Genchi et al. review on aggressive #MultipleSclerosis (EBMT registry, 2,200 pwMS): #AHSCT should be considered early in poor prognosis cases, including DMT non-responders & treatment-naïve with rapid progression.
🟢 More info: journals.sagepub.com/doi/10.1177/...
🔵 Visit curems.net
🟢 More info: journals.sagepub.com/doi/10.1177/...
🔵 Visit curems.net
September 2, 2025 at 2:44 PM
Boffa & Genchi et al. review on aggressive #MultipleSclerosis (EBMT registry, 2,200 pwMS): #AHSCT should be considered early in poor prognosis cases, including DMT non-responders & treatment-naïve with rapid progression.
🟢 More info: journals.sagepub.com/doi/10.1177/...
🔵 Visit curems.net
🟢 More info: journals.sagepub.com/doi/10.1177/...
🔵 Visit curems.net
The ECTRIMS/EBMT consensus (www.nature.com/articles/s41...) states AHSCT should be offered to RRMS patients unresponsive to HE-DMTs. Neurologists and patients must weigh AHSCT’s unique long-term benefits—over 50% achieve NEDA-3 for 10+ years without further therapy. See curems.net/benefits-of-...
July 1, 2025 at 1:18 PM
The ECTRIMS/EBMT consensus (www.nature.com/articles/s41...) states AHSCT should be offered to RRMS patients unresponsive to HE-DMTs. Neurologists and patients must weigh AHSCT’s unique long-term benefits—over 50% achieve NEDA-3 for 10+ years without further therapy. See curems.net/benefits-of-...
CureMS.net screened PubMed and Google Scholar, reviewing 21 studies on RRMS patients treated with AHSCT (intermediate conditioning, 1–10 years follow-up). At 10 years, 40–78% maintained NEDA-3; BEAM+ATG studies reported 55–78%. Total patients: 1145 (possible duplicates). curems.net/benefits-of-...
June 5, 2025 at 2:05 PM
CureMS.net screened PubMed and Google Scholar, reviewing 21 studies on RRMS patients treated with AHSCT (intermediate conditioning, 1–10 years follow-up). At 10 years, 40–78% maintained NEDA-3; BEAM+ATG studies reported 55–78%. Total patients: 1145 (possible duplicates). curems.net/benefits-of-...